Compare PTGX & BILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | BILL |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.6B |
| IPO Year | 2016 | 2019 |
| Metric | PTGX | BILL |
|---|---|---|
| Price | $88.83 | $55.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 23 |
| Target Price | ★ $90.56 | $61.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.3M |
| Earning Date | 11-06-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $209,217,000.00 | ★ $1,499,861,000.00 |
| Revenue This Year | N/A | $12.06 |
| Revenue Next Year | $288.98 | $13.30 |
| P/E Ratio | ★ $123.35 | $463.87 |
| Revenue Growth | N/A | ★ 11.63 |
| 52 Week Low | $33.70 | $36.55 |
| 52 Week High | $96.54 | $100.19 |
| Indicator | PTGX | BILL |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 61.05 |
| Support Level | $84.11 | $52.31 |
| Resistance Level | $90.00 | $57.21 |
| Average True Range (ATR) | 3.31 | 1.51 |
| MACD | -0.75 | 0.08 |
| Stochastic Oscillator | 38.05 | 60.79 |
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.